Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00074854 |
The purpose of this study is to determine whether CP-547,632, an oral VEGFR-2 tyrosine kinase inhibitor when given in combination with chemotherapy (carboplatin and paclitaxel) is effective in the treatment of advanced stage non-small cell lung cancer.
Condition | Intervention | Phase |
---|---|---|
Lung Neoplasms |
Drug: CP-547,632 |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Efficacy Study |
Official Title: | A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy (Paclitaxel And Carboplatin) Vs. Chemotherapy Alone For The Treatment Of Advanced Stage Non-Small Cell Lung Cancer. |
Estimated Enrollment: | 87 |
Study Start Date: | May 2002 |
Estimated Study Completion Date: | March 2005 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Pfizer Investigational Site | |
Greenbrae, California, United States, 94904 | |
Pfizer Investigational Site | |
GREENBRAE, California, United States, 94904 | |
Pfizer Investigational Site | |
San Mateo, California, United States, 94402 | |
Pfizer Investigational Site | |
San Pablo, California, United States, 94806 | |
United States, Florida | |
Pfizer Investigational Site | |
TAMPA, Florida, United States, 33612-9497 | |
United States, Louisiana | |
Pfizer Investigational Site | |
Covington, Louisiana, United States, 70433 | |
Pfizer Investigational Site | |
Metairie, Louisiana, United States, 70002 | |
Pfizer Investigational Site | |
Metairie, Louisiana, United States, 70006 | |
Pfizer Investigational Site | |
New Orleans, Louisiana, United States, 70115 | |
United States, Massachusetts | |
Pfizer Investigational Site | |
Boston, Massachusetts, United States, 02215 | |
United States, New York | |
Pfizer Investigational Site | |
Stony Brook, New York, United States, 11794 | |
United States, Pennsylvania | |
Pfizer Investigational Site | |
Philadelphia, Pennsylvania, United States, 19111 | |
United States, Tennessee | |
Pfizer Investigational Site | |
Gallatin, Tennessee, United States, 37066 | |
Pfizer Investigational Site | |
Hermitage, Tennessee, United States, 37076 | |
Pfizer Investigational Site | |
Lebanon, Tennessee, United States, 37087 | |
Pfizer Investigational Site | |
Murfreesboro, Tennessee, United States, 37130 | |
Pfizer Investigational Site | |
Smyrna, Tennessee, United States, 37167 | |
Pfizer Investigational Site | |
Nashville, Tennessee, United States, 37205 | |
Pfizer Investigational Site | |
Nashville, Tennessee, United States, 37207 | |
Pfizer Investigational Site | |
NASHVILLE, Tennessee, United States, 37211 | |
Pfizer Investigational Site | |
Nashville, Tennessee, United States, 37203 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Study ID Numbers: | A3521002 |
Study First Received: | December 22, 2003 |
Last Updated: | November 8, 2006 |
ClinicalTrials.gov Identifier: | NCT00074854 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Thoracic Neoplasms Respiratory Tract Diseases Paclitaxel Lung Neoplasms Lung Diseases |
Tyrosine Non-small Cell Lung Cancer Carboplatin Carcinoma, Non-Small-Cell Lung |
Thoracic Neoplasms Respiratory Tract Neoplasms Neoplasms Neoplasms by Site |
Respiratory Tract Diseases Lung Neoplasms Lung Diseases |